Latest Sequenom Inc. Stories
VANCOUVER, British Columbia, March 9, 2012 /PRNewswire-Asia/ -- Pennystocksinsiders.com (PSI) has issued insider trading reports and Equity Research for the following companies: Sequenom (NASDAQ:SQNM), Genworth Financial (NYSE:GNW), Huntsman (NYSE:HUN), New Gold (AMEX:NGD), Huntington Bancshares (NASDAQ:HBAN), and Amarin (NASDAQ:AMRN). (Logo: http://photos.prnewswire.com/prnh/20111214/HK22486LOGO ) (Read full report by clicking the link below, you may need to copy and paste the full link to...
SAN DIEGO, Calif., March 8, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced the Company's participation at the Barclays Global Healthcare Conference at the Loews Miami Hotel in Miami, FL on March 13-14, 2012. Ronald M. Lindsay, Ph.D., Director and EVP of Research and Development, will present on Wednesday, March 14, 2012 beginning at 4:15 p.m. ET, to provide an overview of and update on the...
SAN DIEGO, March 7, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today reported total revenues of $15.5 million and $55.9 million for the fourth quarter and full-year of 2011, respectively. Net loss was $22.2 million, or $0.22 per share, and $74.2 million, or $0.75 per share, for the fourth quarter and full-year, respectively. "2011 was a pivotal year for Sequenom as the Sequenom Center for Molecular Medicine...
SAN DIEGO, March 5, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced the Company's participation at the 24th Annual Roth OC Growth Stock Conference at the Ritz-Carlton Hotel in Laguna Niguel, CA on March 11-14, 2012. Dirk van den Boom, Ph.D., SVP of Research and Development, will present on Monday, March 12, 2012 beginning at 5:00 p.m. PT, to provide an overview of and update on the Company....
REDWOOD CITY, Calif., Feb. 23, 2012 /PRNewswire/ -- Verinata Health, Inc., a privately-held company dedicated to maternal and fetal health, announced today that it has commenced an action against Sequenom, Inc. and its wholly-owned subsidiary, Sequenom Center for Molecular Medicine, LLC ("Sequenom CMM"), in federal court. The action, filed in the Northern District of California, seeks a declaratory judgment that Verinata's cell-free DNA sequencing analysis techniques used in its...
SAN DIEGO, Feb. 22, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that it has filed a motion for preliminary injunction against Aria Diagnostics ("Aria") to stop Aria from making, using, selling or offering for sale, importing or exporting, infringing tests for detecting fetal chromosomal aneuploidy, such as Aria's Harmony Prenatal Test(TM), pending the ultimate resolution of the...
SAN DIEGO, Feb. 22, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced it will report financial results for the fourth quarter and full-year 2011 after closing of the NASDAQ Global Market on Wednesday, March 7, 2012. A conference call hosted by Harry F. Hixson, Jr., Ph.D., Chairman and CEO, and other members of senior management will take place on the same day at 5:00pm, ET (2:00pm PT) and will...
SAN DIEGO, Feb. 8, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that its wholly-owned subsidiary, the Sequenom Center for Molecular Medicine (Sequenom CMM), has expanded the application of its recently launched laboratory-developed test (LDT). The Company also announced it has rebranded the test under the name MaterniT21 PLUS, which includes the detection of trisomies 18 and 13 in...
SAN DIEGO, Feb. 2, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that a new publication of an independent multi-center study on Sequenom Center for Molecular Medicine's MaterniT21(TM) laboratory-developed test (LDT) appears today in the online issue of Genetics in Medicine. The study demonstrated the LDT can detect fetal trisomy 21, 18 and 13 with high accuracy from a maternal blood sample...
SAN DIEGO, Jan. 25, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM) today announced the completion of an underwritten public offering of 14,950,000 shares of its common stock, including 1,950,000 shares sold pursuant to the full exercise of an over-allotment option previously granted to the underwriters. All of the shares were offered by Sequenom at a price to the public of $4.15 per share. The gross proceeds to Sequenom from this offering were approximately $62.0 million, before...
